15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials
Reich K, Strober B, Langley R, Song M, Shen Y, You Y, Foley P, Blauvelt A. 15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials. Journal Of The American Academy Of Dermatology 2020, 83: ab145. DOI: 10.1016/j.jaad.2020.06.668.Peer-Reviewed Original ResearchCharacterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
Van Voorhees A, Mason M, Harrold L, Guo N, Guana A, Tian H, Herrera V, Strober B. Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. Journal Of Dermatological Treatment 2020, 32: 907-915. PMID: 32027197, DOI: 10.1080/09546634.2020.1720586.Peer-Reviewed Original ResearchConceptsCorrona Psoriasis RegistrySevere psoriasisPsoriasis RegistryInsufficient respondersPsoriasis body surface areaBody surface areaLogistic regression modelingReal-world studyBiologic therapyPatient demographicsUS patientsBiologic treatmentDisease characteristicsInadequate responseInsufficient responsePatientsPsoriasisDecreased likelihoodRespondersRegistryVisitsRegression modelingEnrollmentFollowOutcomes